NASDAQ:BEAM Beam Therapeutics Q3 2026 Earnings Results & Report $20.86 -0.08 (-0.38%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$21.36 +0.50 (+2.42%) As of 11/20/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Beam Therapeutics missed analyst expectations on both earnings and revenue in its Q3 2026 results, released November 3, 2026. The company reported EPS of -$1.28 versus the -$1.17 consensus estimate, while revenue of $307 thousand fell short of the $8.75 million estimate by $8.44 million. Revenue decreased 96.8% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 3, 2026TimeBefore Market OpensConference Call7:00 AM ET Beam Therapeutics EPS ResultsActual EPS-$1.28Consensus EPS -$1.17Beat/MissMissed by -$0.11One Year Ago EPS-$1.10EPS Beat Rate4 of last 8 quartersBeam Therapeutics Revenue ResultsActual Revenue$307 thousandExpected Revenue$8.75 millionBeat/MissMissed by -$8.44 millionYoY Revenue Growth-96.80%Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Beam Therapeutics Q3 2026 Earnings FAQ Did Beam Therapeutics beat earnings estimates for Q3 2026? Beam Therapeutics (NASDAQ:BEAM) reported earnings of -$1.28 per share for Q3 2026, missing the consensus estimate of -$1.17. The report was announced on Tuesday, November 3, 2026. What was Beam Therapeutics' revenue for Q3 2026? Beam Therapeutics reported revenue of $307 thousand for Q3 2026, against a consensus estimate of $8.75 million. Beam Therapeutics Earnings HeadlinesPositive Trial Results Could Be A Big Moment For Beam Therapeutics (BEAM)November 19 at 3:17 AM | finance.yahoo.comTranscript : Beam Therapeutics Inc. Presents at UBS Global Biopharma Conference 2026, Nov-17-2026 02:00 PMNovember 17, 2026 | marketscreener.comMThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 21 at 1:00 AM | Porter & Company (Ad)Beam Therapeutics Inc. (BEAM) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptNovember 17, 2026 | seekingalpha.comBeam Therapeutics (NASDAQ:BEAM) Price Target Raised to $33.00November 14, 2026 | americanbankingnews.comBeam Therapeutics: Market Selling Promising Data Readouts Doesn't Add UpNovember 12, 2026 | seekingalpha.comSee More Beam Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Beam Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beam Therapeutics and other key companies, straight to your email. Email Address About Beam TherapeuticsBeam Therapeutics (NASDAQ:BEAM) is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development. The company’s research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient’s cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body. Beam is a clinical-stage company focused on developing its programs rather than selling approved medicines. Founded in 2017, Beam is headquartered in Cambridge, Massachusetts. John Evans, a company co-founder, serves as its chief executive officer.View Beam Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in LimboAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestOwens Corning's Stock Slump May Have a Silver Lining for Dividend InvestorsThe Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity StocksHard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.